Published in BMJ on September 07, 1996
Aging and infectious diseases: workshop on HIV infection and aging: what is known and future research directions. Clin Infect Dis (2008) 4.46
Non-injection drug use and HIV disease progression in the era of combination antiretroviral therapy. J Subst Abuse Treat (2011) 1.03
Circumstances at HIV diagnosis and progression of disease in older HIV-infected Americans. Am J Public Health (2001) 1.03
Survival and progression of HIV disease in women attending GUM/HIV clinics in Britain and Ireland. Study Group for the MRC Collaborative Study of HIV Infection in Women. Sex Transm Infect (1999) 0.96
Effect of tuberculosis preventive therapy on HIV disease progression and survival in HIV-infected adults. HIV Clin Trials (2006) 0.94
Association of Y chromosome haplogroup I with HIV progression, and HAART outcome. Hum Genet (2009) 0.94
Cancer, immunodeficiency and antiretroviral treatment: results from the Australian HIV Observational Database (AHOD). HIV Med (2012) 0.93
Methods for estimating HIV prevalence: A comparison of extrapolation from surveys on infection rate and risk behaviour with back-calculation for the Netherlands. Eur J Epidemiol (1998) 0.89
Predictors of virologic response in persons who start antiretroviral therapy during recent HIV infection. AIDS (2014) 0.86
HIV seroconversion interval and demographic characteristics: no evidence of selection bias. Sex Transm Infect (2001) 0.78
Identifying factors associated with changes in CD4(+) count in HIV-infected adults in Saskatoon, Saskatchewan. Can J Infect Dis Med Microbiol (2015) 0.76
Cell-associated infectious HIV-1 viral load as a predictor of clinical progression and survival among HIV-1 infected injection drug users and homosexual men. Eur J Epidemiol (1999) 0.76
Comparison of two measures of human immunodeficiency virus (HIV) type 1 load in HIV risk groups. J Clin Microbiol (1998) 0.75
Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature (1995) 34.97
Viral dynamics in human immunodeficiency virus type 1 infection. Nature (1995) 28.54
Age, thymopoiesis, and CD4+ T-lymphocyte regeneration after intensive chemotherapy. N Engl J Med (1995) 6.77
Race, sex, drug use, and progression of human immunodeficiency virus disease. N Engl J Med (1995) 3.44
Expanded European AIDS case definition. Lancet (1993) 2.45
Laboratory control values for CD4 and CD8 T lymphocytes. Implications for HIV-1 diagnosis. Clin Exp Immunol (1992) 2.27
Risk of developing AIDS in HIV-infected cohorts of hemophilic and homosexual men. JAMA (1989) 1.96
Immunologic dysfunction in heroin addicts. Arch Intern Med (1974) 1.77
Morphine promotes the growth of HIV-1 in human peripheral blood mononuclear cell cocultures. AIDS (1990) 1.61
AIDS incubation in 1891 HIV seroconverters from different exposure groups. International Registry of Seroconverters. AIDS (1990) 1.32
Effect of age and exposure group on the onset of AIDS in heterosexual and homosexual HIV-infected patients. SEROCO Study Group. AIDS (1994) 1.12
Survival in HIV infection: do sex and category of transmission matter? Swiss HIV Cohort Study. AIDS (1994) 1.11
Incidence of symptoms and AIDS in 146 Swedish haemophiliacs and blood transfusion recipients infected with human immunodeficiency virus. BMJ (1988) 1.11
Effect of sex, age and transmission category on the progression to AIDS and survival of zidovudine-treated symptomatic patients. AIDS (1995) 1.10
Changes in markers of disease progression in HIV-1 seroconverters: a comparison between cohorts of injecting drug users and homosexual men. J Acquir Immune Defic Syndr Hum Retrovirol (1995) 1.07
Estimation of the acquired immunodeficiency syndrome incubation period in intravenous drug users: a comparison with male homosexuals. Am J Epidemiol (1992) 1.03
Frequent injecting impairs lymphocyte reactivity in HIV-positive and HIV-negative drug users. AIDS (1991) 1.00
Human immunodeficiency virus type 1 infection: relationship of risk group and age to rate of progression to AIDS. Transfusion Safety Study Group. J Infect Dis (1995) 0.97
The natural history of HIV infection in intravenous drug users: risk of disease progression in a cohort of seroconverters. AIDS (1989) 0.93
Age, the thymus, and T lymphocytes. N Engl J Med (1995) 0.88
Coordinate and independent effects of heroin, cocaine, and alcohol abuse on T-cell E-rosette formation and antigenic marker expression. Clin Immunol Immunopathol (1986) 0.85
Influence of gender, age, and transmission category on the progression from HIV seroconversion to AIDS. J Acquir Immune Defic Syndr (1992) 0.85
Predictors of disease progression in HIV-infected homosexual men with CD4+ cells < 200 x 10(6)/l but free of AIDS-defining clinical disease. AIDS (1994) 0.84
Direct comparison of the relationship between clinical outcome and change in CD4+ lymphocytes in human immunodeficiency virus-positive homosexual men and injecting drug users. Arch Intern Med (1994) 0.83
A comparison of the progression rate to acquired immunodeficiency syndrome between intravenous drug users and homosexual men. Scand J Soc Med (1994) 0.80
HLA and HIV-1: heterozygote advantage and B*35-Cw*04 disadvantage. Science (1999) 8.11
Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet (2003) 7.94
The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA (2000) 7.65
Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet (1998) 7.53
Meta-analysis: principles and procedures. BMJ (1997) 6.87
Risk factors for ischaemic heart disease: the prospective phase of the British Regional Heart Study. J Epidemiol Community Health (1985) 5.53
Mortality, CD4 cell count decline, and depressive symptoms among HIV-seropositive women: longitudinal analysis from the HIV Epidemiology Research Study. JAMA (2001) 5.52
Viral infections in short-term injection drug users: the prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses. Am J Public Health (1996) 5.45
Sex differences in HIV-1 viral load and progression to AIDS. Lancet (1998) 5.24
Effect of a single amino acid change in MHC class I molecules on the rate of progression to AIDS. N Engl J Med (2001) 4.98
Confounding in epidemiological studies: why "independent" effects may not be all they seem. BMJ (1992) 4.79
Self-reported antiretroviral therapy in injection drug users. JAMA (1998) 4.75
Sex differences in risk factors for hiv seroconversion among injection drug users: a 10-year perspective. Arch Intern Med (2001) 4.68
Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection. Hepatology (1999) 4.11
Social class differences in ischaemic heart disease in British men. Lancet (1987) 4.09
Smoking as "independent" risk factor for suicide: illustration of an artifact from observational epidemiology? Lancet (1992) 3.92
Correlates of hepatitis C virus infections among injection drug users. Medicine (Baltimore) (1995) 3.85
Self-reported symptoms and medication side effects influence adherence to highly active antiretroviral therapy in persons with HIV infection. J Acquir Immune Defic Syndr (2001) 3.83
Prevalence of tuberculin positivity and skin test anergy in HIV-1-seropositive and -seronegative intravenous drug users. JAMA (1992) 3.81
Identifying men at high risk of heart attacks: strategy for use in general practice. Br Med J (Clin Res Ed) (1986) 3.76
Prevalence and incidence of hepatitis C virus infection among young adult injection drug users. J Acquir Immune Defic Syndr Hum Retrovirol (1998) 3.68
Genetic acceleration of AIDS progression by a promoter variant of CCR5. Science (1998) 3.60
Time to initiating highly active antiretroviral therapy among HIV-infected injection drug users. AIDS (2001) 3.56
Failure of T-cell homeostasis preceding AIDS in HIV-1 infection. The Multicenter AIDS Cohort Study. Nat Med (1995) 3.46
Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies. Lancet (2003) 3.23
Molecular and geographic patterns of tuberculosis transmission after 15 years of directly observed therapy. JAMA (1998) 3.07
Changes in T-lymphocyte subsets in intravenous drug users with HIV-1 infection. JAMA (1992) 3.07
Effect of Mycobacterium tuberculosis on HIV replication. Role of immune activation. J Immunol (1996) 2.86
Voluntary testing for human immunodeficiency virus (HIV) in a prison population with a high prevalence of HIV. Am J Epidemiol (1994) 2.81
Passive smoking and health: should we believe Philip Morris's "experts"? BMJ (1996) 2.76
Factors associated with adolescent initiation of injection drug use. Public Health Rep (2001) 2.73
Initial plasma HIV-1 RNA levels and progression to AIDS in women and men. N Engl J Med (2001) 2.68
Correlates of HIV infection among young adult short-term injection drug users. AIDS (2000) 2.63
A scoring system to identify men at high risk of a heart attack. Health Trends (1987) 2.58
Comparison of long-term prognosis of patients with AIDS treated and not treated with zidovudine. AIDS in Europe Study Group. JAMA (1994) 2.56
Incidence and risk factors for hepatitis C among injection drug users in Baltimore, Maryland. J Clin Microbiol (1997) 2.55
Using social network analysis to study patterns of drug use among urban drug users at high risk for HIV/AIDS. Drug Alcohol Depend (1995) 2.51
Secondary mutations in the protease region of human immunodeficiency virus and virologic failure in drug-naive patients treated with protease inhibitor-based therapy. J Infect Dis (2001) 2.50
Association between hepatitis E virus and HIV infection in homosexual men. Lancet (1994) 2.49
Seroreactivity to hepatitis E virus in areas where the disease is not endemic. J Clin Microbiol (1997) 2.48
Racial differences in HLA class II associations with hepatitis C virus outcomes. J Infect Dis (2001) 2.47
Concentrations of high density lipoprotein cholesterol, triglycerides, and total cholesterol in ischaemic heart disease. BMJ (1989) 2.47
Antibody responses to Haemophilus influenzae type B vaccines in men with human immunodeficiency virus infection. N Engl J Med (1991) 2.46
Risk factors for stroke in middle aged British men. BMJ (1991) 2.44
The use of the Framingham equation to predict myocardial infarctions in HIV-infected patients: comparison with observed events in the D:A:D Study. HIV Med (2006) 2.38
Incidence and consequences of pregnancy in women with known duration of HIV infection. Italian Seroconversion Study Group. Arch Intern Med (1998) 2.38
Design and baseline participant characteristics of the Human Immunodeficiency Virus Epidemiology Research (HER) Study: a prospective cohort study of human immunodeficiency virus infection in US women. Am J Epidemiol (1997) 2.32
Longitudinal patterns of drug injection behavior in the ALIVE Study cohort,1988-2000: description and determinants. Am J Epidemiol (2003) 2.32
Laboratory control values for CD4 and CD8 T lymphocytes. Implications for HIV-1 diagnosis. Clin Exp Immunol (1992) 2.27
Diagnosed and undiagnosed HIV-infected populations in Europe. HIV Med (2008) 2.26
People and places: behavioral settings and personal network characteristics as correlates of needle sharing. J Acquir Immune Defic Syndr Hum Retrovirol (1996) 2.26
Vitamin A deficiency and wasting as predictors of mortality in human immunodeficiency virus-infected injection drug users. J Infect Dis (1995) 2.25
Genetic restriction of HIV-1 pathogenesis to AIDS by promoter alleles of IL10. Proc Natl Acad Sci U S A (2000) 2.24
Inflation in epidemiology: "the proof and measurement of association between two things" revisited. BMJ (1996) 2.24
Factors affecting survival in patients with the acquired immunodeficiency syndrome. AIDS (1996) 2.22
Factors associated with prevalent hepatitis C: differences among young adult injection drug users in lower and upper Manhattan, New York City. Am J Public Health (2001) 2.21
AIDS across Europe, 1994-98: the EuroSIDA study. Lancet (2000) 2.13
Reactivation and persistence of human herpesvirus-8 infection in B cells and monocytes by Th-1 cytokines increased in Kaposi's sarcoma. Blood (1999) 2.10
Temporal trends of incident human immunodeficiency virus infection in a cohort of injecting drug users in Baltimore, Md. Arch Intern Med (1995) 2.08
Explaining racial disparities in incidence of and survival from out-of-hospital cardiac arrest. Am J Epidemiol (2007) 2.07
Chikungunya in north-eastern Italy: a summing up of the outbreak. Euro Surveill (2007) 2.07
The long-term outcome of a personal network-oriented HIV prevention intervention for injection drug users: the SAFE Study. Am J Community Psychol (1996) 2.07
Effects of CCR5-Delta32, CCR2-64I, and SDF-1 3'A alleles on HIV-1 disease progression: An international meta-analysis of individual-patient data. Ann Intern Med (2001) 2.05
Human herpesvirus 8 seropositivity and risk of Kaposi's sarcoma and other acquired immunodeficiency syndrome-related diseases. J Natl Cancer Inst (1999) 2.01
Socially desirable responding and self-reported HIV infection risk behaviors among intravenous drug users. Addiction (1993) 2.01
Transmission of HIV-1 within a statewide prison system. AIDS (1988) 2.00
Chronic immune activation associated with intestinal helminth infections results in impaired signal transduction and anergy. J Clin Invest (2000) 1.98
Cardio- and cerebrovascular events in HIV-infected persons. AIDS (2004) 1.98
Survival of AIDS patients according to type of AIDS-defining event. The AIDS in Europe Study Group. Int J Epidemiol (1997) 1.97
Discontinuation of Pneumocystis carinii pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection. EuroSIDA Study Group. Lancet (1999) 1.95
Occupational risk of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus infections among funeral service practitioners in Maryland. Infect Control Hosp Epidemiol (1995) 1.95
Migration and geographic variations in ischaemic heart disease in Great Britain. Lancet (1989) 1.95
High frequency of invasive cervical cancer among female injecting drug users with AIDS in Italy. AIDS (1996) 1.92
The association between hepatitis C virus genotype and human immunodeficiency virus disease progression in a cohort of hemophilic men. J Infect Dis (1997) 1.90
Epidemiology of hepatitis B virus infections among injecting drug users: seroprevalence, risk factors, and viral interactions. Epidemiol Rev (1994) 1.87
Reasons for modification and discontinuation of antiretrovirals: results from a single treatment centre. AIDS (2001) 1.86
Compliance with universal precautions among health care workers at three regional hospitals. Am J Infect Control (1995) 1.83
Reference ranges and sources of variability of CD4 counts in HIV-seronegative women and men. Genitourin Med (1996) 1.82
An outbreak of chikungunya fever in the province of Ravenna, Italy. Euro Surveill (2007) 1.81
Gender differences in the initiation of injection drug use among young adults. J Urban Health (2000) 1.78
ABO blood group and ischaemic heart disease in British men. BMJ (1990) 1.76
Antibody to hepatitis C virus among cardiac surgery patients, homosexual men, and intravenous drug users in Baltimore, Maryland. Am J Epidemiol (1991) 1.76
Discarded needles do not increase soon after the opening of a needle exchange program. Am J Epidemiol (1997) 1.76
Syphilis serology in human immunodeficiency virus infection: evidence for false-negative fluorescent treponemal testing. J Infect Dis (1997) 1.74